TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: peripheral endothelial function (EndoScore)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biomarkers of endothelial turnover (sE-Selectin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biomarkers of inflammation (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in 25OHD levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants achieving 25OHD levels >= 75 nmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between central venous catheter and peripheral samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant dose adjustments
Endpoint domain: Adverse events/effects
Primary endpoint: Complete tolerance to cow's milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in cow's milk skin reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in serum-specific IgE to milk and casein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of vascular punctures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum post-baseline Ab3 titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety analysis (adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of headache pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful treatment of teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of ischemic stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Mean stress perfusion defect (summed stress score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Summed difference score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nasal epithelium thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central arterial stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean proportion of blood glucose values within target range (80‐140 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median presyncopal spells per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of incorrect responses in the reaction time test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of errors in the fine manipulation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CBFV (Cerebral Blood Flow Velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of renal function at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: housing stability
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: marginal occlusal adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in daily sitting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival to hospital discharge with favorable neurologic function
Endpoint domain: Mortality/survival
Primary endpoint: HBV DNA suppression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of viable osteocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Increased erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduced trabecular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: NRS scores for pain in the morning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AOFAS functional scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3 to 4 treatment-related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in systolic BP (SBP) and diastolic BP (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clearance of NXY-059
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution of NXY-059
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inducibility of sustained ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major arrhythmic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fewer stimuli required to obtain supramaximal responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower stimuli strength required to obtain supramaximal responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time required to perform ultrasound guidance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HIV RNA levels 51‐1000 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV RNA >1000 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: elevated total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: abnormal triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Boston Naming Test improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: communication-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Drainage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acquisition of subsequent STDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Condom use during last sexual intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proficiency scores for condom application skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of infants with admission temperatures in the target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse reactions to lysozyme-containing cheese
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of Ventricular Tachyarrhythmias (VTA)
Endpoint domain: Mortality/survival
Primary endpoint: improvement in pain coping strategies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in prednicarbate ointment use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Functional capacity in the 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life in SGRQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to stone passage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Modified Rankin Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of VA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of low back disorder
Endpoint domain: Mortality/survival
Primary endpoint: root coverage percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: keratinized tissue increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: felodipine area under the plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: felodipine maximum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAWL (Maximum Acceptable Weight of Lift)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average bond strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average extension at maximum load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed onset of grade 3 oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of delusional domains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-year graft survival
Endpoint domain: Mortality/survival
Primary endpoint: Blood pressure values within national guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reproducibility of PIFn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: normal sperm morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progressive motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of silent ST-segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular systolic and diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diphtheria and tetanus seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-pertussis GMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: improved concentration
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: development of a meaningful smile
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean overall rating
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of gingival fissures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute adverse health effects
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in intraoperative and postoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in thrombotic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative aspirin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebrovascular atherosclerosis and cerebral microangiopathy outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom-from-treatment-failure (FFTF)
Endpoint domain: Mortality/survival
Primary endpoint: Survival (SV)
Endpoint domain: Mortality/survival
Primary endpoint: eGFR (CKD‐EPI‐Creat+CysC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: global language scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stable cognitive status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tolerability of SPX-101
Endpoint domain: Adverse events/effects
Primary endpoint: Mean clinical attachment level gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of radiographic defect depth reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VTA activation in response to social cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Need for stoma placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: End-expiratory lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: EuroQol-5D utility score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: graft rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Headache relief within 15 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache relapse rate
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative tuberculosis rates
Endpoint domain: Mortality/survival
Primary endpoint: 60-day all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Ease of calcium dissolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprocedural bursitis
Endpoint domain: Adverse events/effects
Primary endpoint: Mental status score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median time to PSA progression
Endpoint domain: Mortality/survival
Primary endpoint: Serum lactate dehydrogenase (LDH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise time to 0.1‐mV ST segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of ischemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exercise time to angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of Postural Hypotension (PH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative and early postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Troponin I levels after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lactate levels after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: peak postoperative troponin T levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative live birth delivery rate
Endpoint domain: Mortality/survival
Primary endpoint: Rate of multiple gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Rest-activity rhythm curve (L5 and M10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flow-mediated vasodilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: antral emptying time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: sensation of hunger
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of stroke recurrence
Endpoint domain: Mortality/survival
Primary endpoint: 12-month primary patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite safety endpoint rate
Endpoint domain: Adverse events/effects
Primary endpoint: freedom from TLR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Severity of angiographic vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients in sinus rhythm at follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Demonstration of patent arterial segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: corneal epithelial healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive observer ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: OSA-18 total scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of histologically verified CIN2-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: actual physical activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking abstinence at 3-month follow-up
Endpoint domain: Mortality/survival
Primary endpoint: oral pain intensity and quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain evaluation using VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Endogenous ileal nitrogen flows
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of MEP preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of mean endothelial cell loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-HDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: apolipoprotein-B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Retention rates for vaccinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3-4 complications
Endpoint domain: Adverse events/effects
Primary endpoint: Total iron absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: daily peritoneal Kt/V
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: accuracy of injection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of injection temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IHCL (intrahepatic lipid content)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VLDL1‐TG and apoB fractional catabolic rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cough-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gastroduodenal ulcers post-treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Gastric ulcer rates
Endpoint domain: Adverse events/effects
Primary endpoint: perception of notching and scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Severe hypoglycaemic events
Endpoint domain: Adverse events/effects
Primary endpoint: in-segment late lumen loss (LLL) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sitting office blood pressure (SBP/DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Home blood pressure (SBP/DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average effectiveness (LYS)
Endpoint domain: Mortality/survival
Primary endpoint: Nasal potential difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SSR potential distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal toxicity grade
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant therapeutic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of CMV infection (gB‐absorbed CMV IgG levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to first CMV positive culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of menstrual pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Sultan score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct placement of DLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average time to confirmation of correct tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps motor blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Severity of psychotic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extent of oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall in platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gastric insufflation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: clinical activity of topical CUR61414 in human BCCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: soluble tumour necrosis factor receptor‐2 (sTNF‐R2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: interferon gamma inducible CXCL10 (IP‐10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: soluble L‐selectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes